Contraceptive of choice in a women with Rheumatic heart disease.
**Core Concept**
The question tests the knowledge of contraceptive management in patients with cardiovascular disease, specifically Rheumatic heart disease. The underlying principle is to choose a contraceptive method that does not increase the risk of thromboembolic events or exacerbate the cardiac condition.
**Why the Correct Answer is Right**
In patients with Rheumatic heart disease, the primary concern is the risk of thromboembolic events due to valve damage and potential arrhythmias. The contraceptive of choice should be a method that does not increase this risk. Progesterone-only pills (POPs) are a suitable option as they do not significantly affect blood clotting and are a safer choice in patients with cardiovascular disease. They work by inhibiting ovulation and thickening cervical mucus, thereby preventing fertilization.
**Why Each Wrong Option is Incorrect**
* **Option A:** Combined oral contraceptives (COCs) increase the risk of thromboembolic events by promoting blood clotting, making them a poor choice for patients with Rheumatic heart disease.
* **Option B:** Intrauterine devices (IUDs) are not contraindicated in patients with cardiovascular disease but are not the first-line choice for contraception.
* **Option C:** Depot medroxyprogesterone acetate (DMPA) injections are a form of progesterone-only contraception but may be associated with an increased risk of venous thromboembolism, making them a less desirable option.
**Clinical Pearl / High-Yield Fact**
In patients with cardiovascular disease, progesterone-only pills are generally safer than combined oral contraceptives due to their minimal effect on blood clotting.
**Correct Answer: C. Progesterone-only pills.